Literature DB >> 19002163

Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance.

Kerstin Cornils1, Claudia Lange, Axel Schambach, Martijn H Brugman, Regine Nowak, Michael Lioznov, Christopher Baum, Boris Fehse.   

Abstract

Stable genetic modification of stem cells holds great promise for gene therapy and marking, but commonly used gamma-retroviral vectors were found to influence growth/survival characteristics of hematopoietic stem cells (HSCs) by insertional mutagenesis. In this article, we show that promoter-deprived gamma-retroviral self-inactivating (pd-SIN) vectors allow stable genetic marking of serially reconstituting murine HSC. In contrast to findings with gamma-retroviral long terminal repeat (LTR) vectors, serial transplantation of pd-SIN-marked HSC in a sensitive mouse model was apparently not associated with induced clonal imbalance of gene-marked HSC. Furthermore, insertions of pd-SIN into protooncogenes, growth-promoting and signaling genes occurred significantly less frequent than in control experiments with LTR vectors. Also, transcriptional dysregulation of neighboring genes potentially caused by the pd-SIN insertion was rarely seen and comparatively weak. The integration pattern of promotor-deprived SIN vectors in reconstituting HSC seems to depend on the transcriptional activity of the respective gene loci reflecting the picture described for LTR vectors. In conclusion, our data strongly support the use of SIN vectors for gene-marking studies and suggest an increased therapeutic index for vectors lacking enhancers active in HSC.

Entities:  

Mesh:

Year:  2008        PMID: 19002163      PMCID: PMC2834973          DOI: 10.1038/mt.2008.238

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  47 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Proliferation of totipotent hematopoietic stem cells in vitro with retention of long-term competitive in vivo reconstituting ability.

Authors:  C C Fraser; S J Szilvassy; C J Eaves; R K Humphries
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

3.  Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.

Authors:  Olga Kustikova; Boris Fehse; Ute Modlich; Min Yang; Jochen Düllmann; Kenji Kamino; Nils von Neuhoff; Brigitte Schlegelberger; Zhixiong Li; Christopher Baum
Journal:  Science       Date:  2005-05-20       Impact factor: 47.728

4.  Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque.

Authors:  Ruth Seggewiss; Stefania Pittaluga; Rima L Adler; F Javier Guenaga; Cole Ferguson; Ingo H Pilz; Byoung Ryu; Brian P Sorrentino; W Scott Young; Robert E Donahue; Christof von Kalle; Arthur W Nienhuis; Cynthia E Dunbar
Journal:  Blood       Date:  2006-01-26       Impact factor: 22.113

Review 5.  Genotoxicity of retroviral integration in hematopoietic cells.

Authors:  Arthur W Nienhuis; Cynthia E Dunbar; Brian P Sorrentino
Journal:  Mol Ther       Date:  2006-04-19       Impact factor: 11.454

Review 6.  Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.

Authors:  Christopher Baum; Olga Kustikova; Ute Modlich; Zhixiong Li; Boris Fehse
Journal:  Hum Gene Ther       Date:  2006-03       Impact factor: 5.695

7.  Developmental potential and dynamic behavior of hematopoietic stem cells.

Authors:  I R Lemischka; D H Raulet; R C Mulligan
Journal:  Cell       Date:  1986-06-20       Impact factor: 41.582

8.  Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.

Authors:  H Bobby Gaspar; Emma Bjorkegren; Kate Parsley; Kimberly C Gilmour; Doug King; Joanna Sinclair; Fang Zhang; Aris Giannakopoulos; Stuart Adams; Lynette D Fairbanks; Jane Gaspar; Lesley Henderson; Jin Hua Xu-Bayford; E Graham Davies; Paul A Veys; Christine Kinnon; Adrian J Thrasher
Journal:  Mol Ther       Date:  2006-08-14       Impact factor: 11.454

9.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

10.  Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.

Authors:  Suzan M Hammond; Scott C Crable; Kathleen P Anderson
Journal:  Leuk Res       Date:  2005-01       Impact factor: 3.156

View more
  14 in total

1.  Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.

Authors:  Wenqin Xu; Jill L Russ; Maribeth V Eiden
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

3.  Gene therapy strategies: can we eradicate HIV?

Authors:  Jan van Lunzen; Boris Fehse; Joachim Hauber
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

4.  Gene therapy activates EVI1, destabilizes chromosomes.

Authors:  Cynthia E Dunbar; Andre Larochelle
Journal:  Nat Med       Date:  2010-02       Impact factor: 53.440

5.  RGB marking facilitates multicolor clonal cell tracking.

Authors:  Kristoffer Weber; Michael Thomaschewski; Michael Warlich; Tassilo Volz; Kerstin Cornils; Birte Niebuhr; Maike Täger; Marc Lütgehetmann; Jörg-Matthias Pollok; Carol Stocking; Maura Dandri; Daniel Benten; Boris Fehse
Journal:  Nat Med       Date:  2011-03-27       Impact factor: 53.440

Review 6.  Biosafety features of lentiviral vectors.

Authors:  Axel Schambach; Daniela Zychlinski; Birgitta Ehrnstroem; Christopher Baum
Journal:  Hum Gene Ther       Date:  2013-02       Impact factor: 5.695

7.  SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.

Authors:  Matthias Titeux; Valérie Pendaries; Maria A Zanta-Boussif; Audrey Décha; Nathalie Pironon; Laure Tonasso; José E Mejia; Agnes Brice; Olivier Danos; Alain Hovnanian
Journal:  Mol Ther       Date:  2010-05-18       Impact factor: 11.454

8.  Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells.

Authors:  Marita Bosticardo; Amrita Ghosh; Yang Du; Nancy A Jenkins; Neal G Copeland; Fabio Candotti
Journal:  Mol Ther       Date:  2009-07-28       Impact factor: 11.454

Review 9.  Gene therapy for hemophilia.

Authors:  Geoffrey L Rogers; Roland W Herzog
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

10.  Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.

Authors:  Samantha Scaramuzza; Luca Biasco; Anna Ripamonti; Maria C Castiello; Mariana Loperfido; Elena Draghici; Raisa J Hernandez; Fabrizio Benedicenti; Marina Radrizzani; Monica Salomoni; Marco Ranzani; Cynthia C Bartholomae; Elisa Vicenzi; Andrea Finocchi; Robbert Bredius; Marita Bosticardo; Manfred Schmidt; Christof von Kalle; Eugenio Montini; Alessandra Biffi; Maria G Roncarolo; Luigi Naldini; Anna Villa; Alessandro Aiuti
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.